{"filing":{"accession_number":"0001193125-26-349141","cik":"0000921299","ticker":"KYNB","company_name":"KYNTRA BIO, INC.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"kynb-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/kynb-20260813.htm"},"events":[{"id":27581,"run_id":25149,"accession_number":"0001193125-26-349141","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Kyntra Bio issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue, net income per share, and cash position. The filing discloses condensed consolidated balance sheets and statements of operations for the second quarter and six-month periods, which are typical components of an earnings release. This is a standard quarterly financial results disclosure under Item 2.02.","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29168,"accession_number":"0001193125-26-349141","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Kyntra Bio issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue, net income per share, and cash position. The filing discloses condensed consolidated balance sheets and statements of operations for the second quarter and six-month periods, which are typical components of an earnings release. This is a standard quarterly financial results disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:19.565034+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29168,"accession_number":"0001193125-26-349141","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Kyntra Bio issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue, net income per share, and cash position. The filing discloses condensed consolidated balance sheets and statements of operations for the second quarter and six-month periods, which are typical components of an earnings release. This is a standard quarterly financial results disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:19.565034+00:00","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-08-13"}]}